FORM 4
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden hours per response... 0.5

(Print or Type Responses)
1. Name and Address of Reporting Person *
IPSA (INNOVEN PARTENAIRES S.A.)
   2. Issuer Name and Ticker or Trading Symbol
EYEGATE PHARMACEUTICALS INC [EYEG] 		5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
_____ Director __X__ 10% Owner
_____ Officer (give title below) _____ Other (specify below)
(Last)
(First)
(Middle)
10 RUE DE LA PAIX		 3. Date of Earliest Transaction (Month/Day/Year)
02/19/2015
(Street)

PARIS, I0 75002		 4. If Amendment, Date Original Filed(Month/Day/Year)
 6. Individual or Joint/Group Filing(Check Applicable Line)
_X_ Form filed by One Reporting Person
___ Form filed by More than One Reporting Person
(City)
(State)
(Zip)
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1.Title of Security
(Instr. 3)		 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code
(Instr. 8)		 4. Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5)		 5. Amount of Securities Beneficially Owned Following Reported Transaction(s)
(Instr. 3 and 4)		 6. Ownership Form: Direct (D) or Indirect (I)
(Instr. 4)		 7. Nature of Indirect Beneficial Ownership
(Instr. 4)
Code V Amount (A) or (D) Price
Common Stock 02/19/2015   C   524,998 A (1) 524,998 I See Footnote (2) (3)
Common Stock 02/19/2015   C   169,306 A (4) 694,304 I See Footnote (2) (5)
Common Stock 02/19/2015   C   261,314 A (6) 955,618 I See Footnote (2) (7)
Common Stock 02/19/2015   C   138,194 A $ 4.2 1,093,812 I See Footnote (2) (8)
Common Stock 02/19/2015   P   366,667 A $ 6 1,460,479 I See Footnote (2) (9)

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number. SEC 1474 (9-02)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security
(Instr. 3)		 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code
(Instr. 8)		 5. Number of Derivative Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4, and 5)		 6. Date Exercisable and Expiration Date
(Month/Day/Year)		 7. Title and Amount of Underlying Securities
(Instr. 3 and 4)		 8. Price of Derivative Security
(Instr. 5)		 9. Number of Derivative Securities Beneficially Owned Following Reported Transaction(s)
(Instr. 4)		 10. Ownership Form of Derivative Security: Direct (D) or Indirect (I)
(Instr. 4)		 11. Nature of Indirect Beneficial Ownership
(Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Series B Preferred Stock (1) 02/19/2015   C     524,998   (1)   (1) Common Stock 524,998 $ 0 0 I See Footnote (2) (3)
Series C Preferred Stock (4) 02/19/2015   C     169,306   (4)   (4) Common Stock 169,306 $ 0 0 I See Footnote (2) (5)
Series D Preferred Stock (6) 02/19/2015   C     261,314   (6)   (6) Common Stock 261,314 $ 0 0 I See Footnote (2) (7)
Convertible Promissory Note $ 4.2 02/19/2015   P   $ 580,415   02/19/2015 06/06/2015 Common Stock 138,194 $ 580,415 $ 580,415 I See Footnote (2) (10)
Convertible Promissory Note $ 4.2 02/19/2015   C     $ 580,415 02/19/2015 06/06/2015 Common Stock 138,194 $ 0 0 I See Footnote (2) (10)

Reporting Owners

Reporting Owner Name / Address Relationships
 Director  10% Owner  Officer  Other
IPSA (INNOVEN PARTENAIRES S.A.)
10 RUE DE LA PAIX
PARIS, I0 75002		     X    

Signatures

 /s/ Authorized Signatory*   02/23/2015
**Signature of Reporting Person Date

Explanation of Responses:

* If the form is filed by more than one reporting person, see Instruction 4(b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
(1) Upon closing of the Issuer's initial public offering, each share of Series B Preferred Stock converted automatically into shares of common stock of the Issuer on a 10.94-for-one basis, and had no expiration date.
(2) Innoven Partenaires S.A. ("IPSA") is the manager of each of Innoven 2002 FCPI No.6, Innoven 2003 FCPI No.7, FCPI Innoven Europe, FCPI Innoven Europe 2, FCPI Innoven Europe 3, FCPI Innoven Capital, FCPI Innoven Capital 2, FCPI Poste Innovation, FCPI Poste Innovation 2, FCPI Poste Innovation 3, FCPI Poste Innovation 5, FCPI Poste Innovation 6, FCPI Poste Innovation 9 and FCPI La Banque Postale Innovation 1 (collectively, the "Funds"). Voting and investment power over the shares held by each of the Funds may be deemed to be shared with IPSA. Each of Jean-Michel Paulhac ("Paulhac") and Thomas Balland ("Balland ") are directors of IPSA. Each of Paulhac and Balland disclaims beneficial ownership of these securities and this report shall not be deemed an admission that any of them is the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of their pecuniary interest therein.
(3) Represents 26,994, 71,111, 16,416, 711,099, 428,115, 599,019, 817,685, 2,203,862, 885,941, and 4,288 shares held by Innoven 2002 FCPI No.6, Innoven 2003 FCPI No.7, FCPI Innoven Europe, FCPI Poste Innovation, FCPI Poste Innovation 2, FCPI Poste Innovation 3, FCPI Poste Innovation 5, FCPI Poste Innovation 6, FCPI Poste Innovation 9, and FCPI La Banque Postale Innovation 1, respectively.
(4) Upon closing of the Issuer's initial public offering, each share of Series C Preferred Stock converted automatically into shares of common stock of the Issuer on a 9.60-for-one basis, and had no expiration date.
(5) Represents 324,574, 31,532, 217,235, 89,946, 139,349, 269,507 and 786,837 shares held by FCPI Innoven Europe, FCPI Innoven Europe 2, FCPI Poste Innovation, FCPI Poste Innovation 2, FCPI Poste Innovation 3, FCPI Poste Innovation 5 and FCPI La Banque Postale Innovation 1, respectively.
(6) Upon closing of the Issuer's initial public offering, each share of Series D Preferred Stock converted automatically into shares of common stock of the Issuer on a 10.96-for-one basis, and had no expiration date.
(7) Represents 1,163, 527,940, 429,985, 361,720, 84,327, 920,096, 219,702, 219,862, 216 and 104,236 shares held by FCPI Innoven Europe, FCPI Innoven Europe 2, FCPI Innoven Europe 3, FCPI Innoven Capital, FCPI Innoven Capital 2, FCPI Poste Innovation, FCPI Poste Innovation 2, FCPI Poste Innovation 3, and FCPI La Banque Postale Innovation 1, respectively.
(8) Represents 5,791, 7,865, 31,161, 50,953, 39,160, 32,943, 7,680, 230,238, 149,680, 193,633, 210,214, 200,716, 80,706 and 81,544 shares held by Innoven 2002 FCPI No.6, Innoven 2003 FCPI No.7, FCPI Innoven Europe, FCPI Innoven Europe 2, FCPI Innoven Europe 3, FCPI Innoven Capital, FCPI Innoven Capital 2, FCPI Poste Innovation, FCPI Poste Innovation 2, FCPI Poste Innovation 3, FCPI Poste Innovation 5, FCPI Poste Innovation 6, FCPI Poste Innovation 9 and FCPI La Banque Postale Innovation 1, respectively.
(9) Represents 5,791, 10,006, 36,191, 64,167, 39,160, 32,943, 15,230, 230,238, 149,680, 193,633, 280,566, 231,074, 80,706 and 91,103 shares held by Innoven 2002 FCPI No.6, Innoven 2003 FCPI No.7, FCPI Innoven Europe, FCPI Innoven Europe 2, FCPI Innoven Europe 3, FCPI Innoven Capital, FCPI Innoven Capital 2, FCPI Poste Innovation, FCPI Poste Innovation 2, FCPI Poste Innovation 3, FCPI Poste Innovation 5, FCPI Poste Innovation 6, FCPI Poste Innovation 9 and FCPI La Banque Postale Innovation 1, respectively.
(10) Represents 2,141, 5,030, 13,214, 7,550, 70,342, 30,358 and 9,559 shares held by Innoven 2003 FCPI No.7, FCPI Innoven Europe, FCPI Innoven Europe 2, FCPI Innoven Capital 2, FCPI Poste Innovation 5, FCPI Poste Innovation 6 and FCPI La Banque Postale Innovation 1, respectively.
 
Remarks:
*Signed under power of attorney on behalf of Reporting Person

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.